Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYX-783 in PTSD
NCT04044664Phase 2Completed
- Sponsor
- Aptinyx Inc.
- Start
- Jan 2019
- Primary completion
- Aug 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NYX-783 in post-traumatic stress disorder (PTSD), sponsored by Aptinyx Inc.. Started Jan 2019; status: completed.
02
Drugs
NYX-783
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04044664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044664.